Close

Northwest Biotherapeutics (NWBO) Reports Survival Data from DCVax®-L Study

March 27, 2015 9:08 AM EDT Send to a Friend
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login